PR Newswire TechnologyCodex · 实盘不做把握 8/10不做原因:无增量信息🔁 +1 同一事件
北京时间·🕒 发布 18:30:00·⟳ 抓取 18:30:20 +20s·⚡ 决策 09-01 18:50:17 +19m57s·56.1 天前
Bio-Techne 获 SBTi 气候目标验证并披露减排进展
该事件对公司声誉和客户 ESG 合规形象偏正面，但没有披露新增销售、利润、合同、补贴、成本节约金额或监管准入变化，无法建立可执行的正期望交易。
📄 原文PR Newswire Technology↗ 原文
Fiscal 2026 highlights: - Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduc…
不做 Bio-Techne Corporation（TECH.US）
ESG/气候目标验证缺少订单、收入、利润、成本节约或准入增量，无法形成短线可交易 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Bio-Techne（TECH.US）本次披露的是 SBTi 气候目标验证和减排进度，事实清晰但属于可持续发展层面的确认性信息；公告自身没有显示对 12 亿美元以上年销售基数产生可量化业绩增量，也没有改变生命科学工具、试剂或诊断产品需求，因此不做。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 medium ↗
关键理由
- SBTi 验证和可再生电力进展主要提升 ESG 披露质量，不直接改变 Bio-Techne 的订单、收入或利润斜率。
- 公告未给出节能降本金额或客户采购承诺，无法从超过 12 亿美元净销售基数推导可交易的新增业绩占比。
主要风险
- 若后续公司披露大型客户因 SBTi 目标验证新增采购或供应商准入，事件性质才可能从 ESG 披露转为商业化催化。
先例如何影响了这次决策
对本次决策的影响:先例不足不影响结论，事件本身已足以判定无可执行 edge。
方向:未使用先例；ESG 目标验证类公告缺少直接经营或资本市场机制，先例不会改变本次不做判断。
涨幅量级:未校准交易幅度，因为没有进入交易决策。
形态:未评估见光死模式；本次核心问题是没有可量化业绩增量。
原文全文
展开原文 · 3,133 字
Fiscal 2026 highlights:
- Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets
- Market-based Scope 1 and 2 emissions reduced 49% year-over-year
- More than half of the company's electricity consumption now comes from renewable sources
- First comprehensive Scope 3 emissions inventory completed
MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
The SBTi validated Bio-Techne's targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031 from a fiscal year 2025 baseline and to commit that 81% of suppliers by spend covering purchased goods and services, capital goods, upstream transportation and distribution and business travel will have science-based targets by fiscal year 2030.
Validation of the greenhouse gas reduction targets provides customers, suppliers and other stakeholders with independent confirmation that the Company's climate goals are aligned with recognized global standards and climate science.
"Our Science Based Targets validation and progress against those targets demonstrate Bio-Techne's commitment to growing responsibly," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "As we support scientific and diagnostic innovation around the world, we are also taking meaningful steps to reduce our environmental impact and strengthen sustainability across our operations and value chain."
Bio-Techne also expanded its use of renewable electricity during the year. The company transitioned its Minneapolis headquarters to 100% renewable electricity and began procuring renewable electricity for its St. Paul GMP facility. As a result, renewable sources now account for 51% of Bio-Techne's total electricity consumption.
ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.
CONTACT:
Corporate Communications
[email protected]
David Clair, Vice President
Investor Relations
[email protected]
SOURCE Bio-Techne Corporation
- Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets
- Market-based Scope 1 and 2 emissions reduced 49% year-over-year
- More than half of the company's electricity consumption now comes from renewable sources
- First comprehensive Scope 3 emissions inventory completed
MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
The SBTi validated Bio-Techne's targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031 from a fiscal year 2025 baseline and to commit that 81% of suppliers by spend covering purchased goods and services, capital goods, upstream transportation and distribution and business travel will have science-based targets by fiscal year 2030.
Validation of the greenhouse gas reduction targets provides customers, suppliers and other stakeholders with independent confirmation that the Company's climate goals are aligned with recognized global standards and climate science.
"Our Science Based Targets validation and progress against those targets demonstrate Bio-Techne's commitment to growing responsibly," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "As we support scientific and diagnostic innovation around the world, we are also taking meaningful steps to reduce our environmental impact and strengthen sustainability across our operations and value chain."
Bio-Techne also expanded its use of renewable electricity during the year. The company transitioned its Minneapolis headquarters to 100% renewable electricity and began procuring renewable electricity for its St. Paul GMP facility. As a result, renewable sources now account for 51% of Bio-Techne's total electricity consumption.
ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.
CONTACT:
Corporate Communications
[email protected]
David Clair, Vice President
Investor Relations
[email protected]
SOURCE Bio-Techne Corporation
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。